What does SOCIETE NEUROLOGIE CLAES do?

SOCIETE NEUROLOGIE CLAES is a specialist medical practice in Rouvroy. Private Limited, started on 23 June 2016, 2 establishments.

What is the address of SOCIETE NEUROLOGIE CLAES?

The registered office of SOCIETE NEUROLOGIE CLAES is located at Rue Escofiette,Torgny 1, 6767 Rouvroy.

Is SOCIETE NEUROLOGIE CLAES still active?

Yes. According to the CBE (29 October 2026) SOCIETE NEUROLOGIE CLAES is active, legal situation “Normale toestand”, started on 23 June 2016.

Is SOCIETE NEUROLOGIE CLAES registered on Peppol?

Yes, SOCIETE NEUROLOGIE CLAES is registered on the Peppol network with ID 0208:0656917256.

What is the enterprise number of SOCIETE NEUROLOGIE CLAES?

The enterprise number of SOCIETE NEUROLOGIE CLAES is BE0656917256.

When was SOCIETE NEUROLOGIE CLAES founded?

SOCIETE NEUROLOGIE CLAES was founded on 23 June 2016.

Who are the directors of SOCIETE NEUROLOGIE CLAES?

According to the 2025 annual accounts, the directors of SOCIETE NEUROLOGIE CLAES are: Frédérique Claes.

Is SOCIETE NEUROLOGIE CLAES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 June 2016; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did SOCIETE NEUROLOGIE CLAES make in 2025?

SOCIETE NEUROLOGIE CLAES posted a profit after taxes of € 26,382 in financial year 2025.

What is the revenue of SOCIETE NEUROLOGIE CLAES?

As a small company, SOCIETE NEUROLOGIE CLAES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 62,949.

SOCIETE NEUROLOGIE CLAES (Private Limited) - Rouvroy

Dossier SOCIETE NEUROLOGIE CLAES, printed on 29 October 2026 from databakkes.be/en/0656917256/societe-neurologie-claes. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

SOCIETE NEUROLOGIE CLAES from Rouvroy, company number BE0656917256, closed financial year 2025 with a result of € 26,382 after tax. For that financial year SOCIETE NEUROLOGIE CLAES recorded a gross margin of € 62,949 and equity of € 86,572. Compared with financial year 2024, the result moved from € 19,068 to € 26,382. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Growing

€ 86,572

▲ 42% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 26,382

▲ 38% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 109,326

▲ 96% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

3 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 1,409 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 1,409

▼ 33% vs 2024

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 4,840

▲ 64% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 29,693

▼ 43% vs 2024

€ 23,988 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 2,004

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 12,203

▲ 13% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 86,156 Gross margin 2022: € 86,156 First fiscal year in the series	€ 27,338 Gross margin 2023: € 27,338 ▼ 68% vs 2022 (€ 86,156) Unfavourable step	€ 48,501 Gross margin 2024: € 48,501 ▲ 77% vs 2023 (€ 27,338) Favourable step	€ 62,949 Gross margin 2025: € 62,949 ▲ 30% vs 2024 (€ 48,501) Favourable step	▲ 30%
Profit after taxes	€ 30,570 Profit after taxes 2022: € 30,570 First fiscal year in the series	€ -4,170 Profit after taxes 2023: € -4,170 ▼ € 34,740 vs 2022 (€ 30,570) Unfavourable step	€ 19,068 Profit after taxes 2024: € 19,068 ▲ € 23,238 vs 2023 (€ -4,170) Favourable step	€ 26,382 Profit after taxes 2025: € 26,382 ▲ 38% vs 2024 (€ 19,068) Favourable step	▲ 38%
Equity	€ 73,838 Equity 2022: € 73,838 First fiscal year in the series	€ 69,668 Equity 2023: € 69,668 ▼ 6% vs 2022 (€ 73,838) Unfavourable step	€ 61,023 Equity 2024: € 61,023 ▼ 12% vs 2023 (€ 69,668) Unfavourable step	€ 86,572 Equity 2025: € 86,572 ▲ 42% vs 2024 (€ 61,023) Favourable step	▲ 42%
Total debts	€ 196,350 Total debts 2022: € 196,350 First fiscal year in the series	€ 104,743 Total debts 2023: € 104,743 ▼ 47% vs 2022 (€ 196,350) Favourable step	€ 96,660 Total debts 2024: € 96,660 ▼ 8% vs 2023 (€ 104,743) Favourable step	€ 52,389 Total debts 2025: € 52,389 ▼ 46% vs 2024 (€ 96,660) Favourable step	▼ 46%
Cash	€ 167,965 Cash 2022: € 167,965 First fiscal year in the series	€ 78,677 Cash 2023: € 78,677 ▼ 53% vs 2022 (€ 167,965) Unfavourable step	€ 55,818 Cash 2024: € 55,818 ▼ 29% vs 2023 (€ 78,677) Unfavourable step	€ 109,326 Cash 2025: € 109,326 ▲ 96% vs 2024 (€ 55,818) Favourable step	▲ 96%
Land & buildings	€ 2,876 Land & buildings 2022: € 2,876 First fiscal year in the series	€ 2,535 Land & buildings 2023: € 2,535 ▼ 12% vs 2022 (€ 2,876) Unchanged	€ 2,193 Land & buildings 2024: € 2,193 ▼ 13% vs 2023 (€ 2,535) Unchanged	€ 1,851 Land & buildings 2025: € 1,851 ▼ 16% vs 2024 (€ 2,193) Unchanged	▼ 16%
Retained profit	€ 55,238 Retained profit 2022: € 55,238 First fiscal year in the series	€ 51,068 Retained profit 2023: € 51,068 ▼ 8% vs 2022 (€ 55,238) Unfavourable step	€ 42,423 Retained profit 2024: € 42,423 ▼ 17% vs 2023 (€ 51,068) Unfavourable step	€ 67,972 Retained profit 2025: € 67,972 ▲ 60% vs 2024 (€ 42,423) Favourable step	▲ 60%
Dividend	€ 72,311 Dividend 2022: € 72,311 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 72,311) Unchanged	€ 14,898 Dividend 2024: € 14,898 Unchanged (€ 0) Unchanged	€ 833 Dividend 2025: € 833 ▼ 94% vs 2024 (€ 14,898) Unchanged	▼ 94%
Bank debt	€ 107,920 Bank debt 2022: € 107,920 First fiscal year in the series	€ 88,880 Bank debt 2023: € 88,880 ▼ 18% vs 2022 (€ 107,920) Favourable step	€ 52,043 Bank debt 2024: € 52,043 ▼ 41% vs 2023 (€ 88,880) Favourable step	€ 29,693 Bank debt 2025: € 29,693 ▼ 43% vs 2024 (€ 52,043) Favourable step	▼ 43%
Balance sheet total	€ 270,188 Balance sheet total 2022: € 270,188 First fiscal year in the series	€ 174,411 Balance sheet total 2023: € 174,411 ▼ 35% vs 2022 (€ 270,188) Unchanged	€ 157,683 Balance sheet total 2024: € 157,683 ▼ 10% vs 2023 (€ 174,411) Unchanged	€ 138,961 Balance sheet total 2025: € 138,961 ▼ 12% vs 2024 (€ 157,683) Unchanged	▼ 12%

Key figures of SOCIETE NEUROLOGIE CLAES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SOCIETE NEUROLOGIE CLAES?

What happened at SOCIETE NEUROLOGIE CLAES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: profit of € 26,382 (▲ 38% vs 2024). Source: NBB ↗
2022 Frédérique Claes became a director. NBB
Jun 23, 2016 New establishment in Arlon. KBO
Jun 23, 2016 New establishment in Liège. KBO
Jun 23, 2016 Start of the company according to the CBE. KBO

In short

From € 30,570 profit in 2022 to € 26,382 profit in 2025.

Paid € 21,769 in corporate taxes since 2022.

Best year ever: 2022, with € 30,570 profit.

Paid out € 88,042 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Frédérique Claes

SOCIETE NEUROLOGIE CLAES

Behind SOCIETE NEUROLOGIE CLAES is Frédérique Claes.

Directors

According to the 2025 annual accounts

Frédérique Claes

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Escofiette,Torgny 1

6767 Rouvroy

2.254.933.066

Rue de Bitburg 19 box 5

6700 Arlon

Active since 23 June 2016

2.254.933.165

Avenue de l'Hôpital 1

4000 Liège

Active since 23 June 2016

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

ECLIPSE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0656.917.256
VAT number: BE 0656.917.256
Registered office: Rue Escofiette,Torgny 1, 6767 Rouvroy
Names & denominations: SOCIETE NEUROLOGIE CLAES · SONEUCLA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 23 June 2016
Peppol: Active · Active since 17 Sept 2025
Contact: [email protected]
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗